Patents by Inventor Dieter Krimmer

Dieter Krimmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9090582
    Abstract: Described is pentamycin in a purity exceeding 95%, certain polymorphs and solvates of pentamycin, processes for their manufacture, and a method for decreasing the rate of degradation of pentamycin.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: July 28, 2015
    Assignee: Biolotus Biotechnology AG
    Inventors: Karl Reuter, Victor Meier, Florian Stolz, Dieter Krimmer, Cees Winninps
  • Publication number: 20140094602
    Abstract: Described is pentamycin in a purity exceeding 95%, certain polymorphs and solvates of pentamycin, processes for their manufacture, and a method for decreasing the rate of degradation of pentamycin.
    Type: Application
    Filed: July 22, 2013
    Publication date: April 3, 2014
    Applicant: Biolotus Biotechnology AG
    Inventors: Karl REUTER, Victor Meier, Florian Stolz, Dieter Krimmer, Cees Winninps
  • Patent number: 8519162
    Abstract: Described is pentamycin in a purity exceeding 95%, certain polymorphs and solvates of pentamycin, processes for their manufacture, and a method for decreasing the rate of degradation of pentamycin.
    Type: Grant
    Filed: March 20, 2009
    Date of Patent: August 27, 2013
    Assignee: Biolotus Biotechnology AG
    Inventors: Karl Reuter, Viktor Meier, Florian Stolz, Dieter Krimmer, Cees Winninps
  • Publication number: 20110077398
    Abstract: Described is pentamycin in a purity exceeding 95%, certain polymorphs and solvates of pentamycin, processes for their manufacture, and a method for decreasing the rate of degradation of pentamycin.
    Type: Application
    Filed: March 20, 2009
    Publication date: March 31, 2011
    Inventors: Karl Reuter, Viktor Meier, Florian Stolz, Dieter Krimmer, Cees Winninps
  • Publication number: 20050282757
    Abstract: A method for preventing thrombosis in a setting where rapid onset and/or rapid offset of anticoagulation is required, comprising administering a compound selected from the group consisting of boronic acids which have a neutral thrombin P1 domain linked to a hydrophobic moiety capable of binding to the thrombin S2 and S3 subsites, and pharmaceutically acceptable salts, prodrugs and pharmaceutically acceptable prodrug salts of such acids.
    Type: Application
    Filed: March 9, 2005
    Publication date: December 22, 2005
    Inventors: Sophie Combe-Marzelle, Anthony Kennedy, Graham Allen, Roger Withington, Dieter Krimmer
  • Publication number: 20050176651
    Abstract: Tripeptide boronic acids of (R,S,R) configuration, for example Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)2, and their use to make base addition salts of such acids. The salts are formulated into anti-thrombotic pharmaceutical formulations.
    Type: Application
    Filed: September 8, 2004
    Publication date: August 11, 2005
    Inventors: David Madge, Mark Dolman, Armin Walter, Dieter Krimmer, John Deadman, Alfred Olbrich, Andrea Weiland-Waibel
  • Publication number: 20050119226
    Abstract: Organoboronic acids, for example Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)2, are made by hydrolysing their diethanolamine adducts under conditions which avoid substantial C—B bond breakage. The product acids are substantially free of degradation product derived from cleavage of the C—B bond thereof. The acids are used to make base addition salts thereof. The salts are formulated into anti-thrombotic pharmaceutical formulations.
    Type: Application
    Filed: September 8, 2004
    Publication date: June 2, 2005
    Inventors: Armin Walter, Alfred Olbrich, Andrea Weiland-Waibel, Dieter Krimmer